These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28219749)

  • 21. Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets.
    Pearce RK; Costa S; Jenner P; Marsden CD
    J Neural Transm (Vienna); 1999; 106(7-8):663-83. PubMed ID: 10907726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Voxel-based morphometry of the marmoset brain: In vivo detection of volume loss in the substantia nigra of the MPTP-treated Parkinson's disease model.
    Hikishima K; Ando K; Komaki Y; Kawai K; Yano R; Inoue T; Itoh T; Yamada M; Momoshima S; Okano HJ; Okano H
    Neuroscience; 2015 Aug; 300():585-92. PubMed ID: 26012491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral treatment with the NADPH oxidase antagonist apocynin mitigates clinical and pathological features of parkinsonism in the MPTP marmoset model.
    Philippens IH; Wubben JA; Finsen B; 't Hart BA
    J Neuroimmune Pharmacol; 2013 Jun; 8(3):715-26. PubMed ID: 23504289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postural changes after lesions of the substantia nigra pars reticulata in hemiparkinsonian monkeys.
    Henderson JM; Stanic D; Tomas D; Patch J; Horne MK; Bourke D; Finkelstein DI
    Behav Brain Res; 2005 May; 160(2):267-76. PubMed ID: 15863223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurometabolic profiles of the substantia nigra and striatum of MPTP-intoxicated common marmosets: An in vivo proton MRS study at 9.4 T.
    Heo H; Ahn JB; Lee HH; Kwon E; Yun JW; Kim H; Kang BC
    NMR Biomed; 2017 Feb; 30(2):. PubMed ID: 28028868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex differences in motor behavior in the MPTP mouse model of Parkinson's disease.
    Antzoulatos E; Jakowec MW; Petzinger GM; Wood RI
    Pharmacol Biochem Behav; 2010 Jun; 95(4):466-72. PubMed ID: 20347863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset.
    Jenner P; Zeng BY; Smith LA; Pearce RK; Tel B; Chancharme L; Moachon G
    Exp Brain Res; 2000 Jul; 133(2):178-88. PubMed ID: 10968218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-Parkinson effects of a selective alpha2C-adrenoceptor antagonist in the MPTP marmoset model.
    Philippens IH; Joosen MJ; Ahnaou A; Andres I; Drinkenburg WP
    Behav Brain Res; 2014 Aug; 269():81-6. PubMed ID: 24769173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
    Iravani MM; Costa S; Jackson MJ; Tel BC; Cannizzaro C; Pearce RK; Jenner P
    Eur J Neurosci; 2001 Feb; 13(3):597-608. PubMed ID: 11168568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets.
    Costa S; Iravani MM; Pearce RK; Jenner P
    Eur J Pharmacol; 2001 Jan; 412(1):45-50. PubMed ID: 11166735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Orexin-B exerts excitatory effects on nigral dopaminergic neurons and alleviates motor disorders in MPTP parkinsonian mice.
    Bian K; Liu C; Wang Y; Xue Y; Chen L
    Neurosci Lett; 2021 Nov; 765():136291. PubMed ID: 34666119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.
    Hamadjida A; Nuara SG; Veyres N; Frouni I; Kwan C; Sid-Otmane L; Harraka MJ; Gourdon JC; Huot P
    Psychopharmacology (Berl); 2017 Mar; 234(6):905-911. PubMed ID: 28130646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Behavior, PET and histology in novel regimen of MPTP marmoset model of Parkinson's disease for long-term stem cell therapy.
    Yun JW; Ahn JB; Kwon E; Ahn JH; Park HW; Heo H; Park JS; Kim H; Paek SH; Kang BC
    Tissue Eng Regen Med; 2016 Feb; 13(1):100-109. PubMed ID: 30603390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson's disease.
    Patki G; Lau YS
    Pharmacol Biochem Behav; 2011 Oct; 99(4):704-11. PubMed ID: 21741988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson's disease in marmoset monkeys.
    Eslamboli A; Baker HF; Ridley RM; Annett LE
    Exp Neurol; 2003 Oct; 183(2):418-29. PubMed ID: 14552882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.
    Blesa J; Pifl C; Sánchez-González MA; Juri C; García-Cabezas MA; Adánez R; Iglesias E; Collantes M; Peñuelas I; Sánchez-Hernández JJ; Rodríguez-Oroz MC; Avendaño C; Hornykiewicz O; Cavada C; Obeso JA
    Neurobiol Dis; 2012 Oct; 48(1):79-91. PubMed ID: 22677034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
    Kuoppamäki M; Al-Barghouthy G; Jackson M; Smith L; Zeng BY; Quinn N; Jenner P
    Mov Disord; 2002 Nov; 17(6):1312-7. PubMed ID: 12465074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Charting the onset of Parkinson-like motor and non-motor symptoms in nonhuman primate model of Parkinson's disease.
    Choudhury GR; Daadi MM
    PLoS One; 2018; 13(8):e0202770. PubMed ID: 30138454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.